Aurobindo Pharma Limited (NSE:AUROPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Aurobindo Pharma Limited (AUROPHARMA)
Aurobindo Pharma Limited (NSE:AUROPHARMA) has a market capitalization of $8.73 Billion (Rs807.02 Billion) as of May 2, 2026. Listed on the NSE stock exchange, this India-based company holds position #2469 globally and #98 in its home market, demonstrating a -2.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aurobindo Pharma Limited's stock price Rs1389.50 by its total outstanding shares 580801623 (580.80 Million). Analyse AUROPHARMA cash flow conversion to see how efficiently the company converts income to cash.
Aurobindo Pharma Limited Market Cap History: 2015 to 2026
Aurobindo Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $5.23 Billion to $8.73 Billion (5.81% CAGR).
Index Memberships
Aurobindo Pharma Limited is a constituent of 12 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$86.64 Billion | 10.07% | #5 of 20 |
|
NIFTY GROWTH SECTORS 15
NI15
|
$263.61 Billion | 3.31% | #10 of 15 |
|
NIFTY MIDCAP 100
NIFMDCP100
|
$519.63 Billion | 1.68% | #16 of 100 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$1.79 Trillion | 0.49% | #56 of 99 |
|
NIFTY 200
NIFTY200
|
$2.56 Trillion | 0.34% | #87 of 200 |
|
NIFTY 500
NIFTY500
|
$3.11 Trillion | 0.28% | #89 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$102.93 Billion | 8.48% | #7 of 20 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$695.80 Billion | 1.25% | #18 of 150 |
|
NIFTY MIDCAP SELECT
NIFTYMIDSELECT
|
$164.91 Billion | 5.29% | #7 of 25 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.11 Trillion | 0.79% | #26 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.27% | #89 of 750 |
|
NIFTY MIDCAP 50
NIMDCP50
|
$293.61 Billion | 2.97% | #11 of 50 |
Weight: Aurobindo Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aurobindo Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aurobindo Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Aurobindo Pharma Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.21x
Aurobindo Pharma Limited's market cap is 0.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.01 Billion | $138.16 Billion | $20.25 Billion | 0.03x | 0.20x |
| 2017 | $4.14 Billion | $149.33 Billion | $23.02 Billion | 0.03x | 0.18x |
| 2018 | $4.43 Billion | $164.63 Billion | $24.23 Billion | 0.03x | 0.18x |
| 2019 | $2.78 Billion | $195.64 Billion | $23.65 Billion | 0.01x | 0.12x |
| 2020 | $5.62 Billion | $230.99 Billion | $28.45 Billion | 0.02x | 0.20x |
| 2021 | $4.50 Billion | $247.75 Billion | $53.35 Billion | 0.02x | 0.08x |
| 2022 | $2.72 Billion | $234.55 Billion | $26.48 Billion | 0.01x | 0.10x |
| 2023 | $6.81 Billion | $248.55 Billion | $19.27 Billion | 0.03x | 0.35x |
| 2024 | $8.38 Billion | $290.02 Billion | $31.73 Billion | 0.03x | 0.26x |
| 2025 | $7.43 Billion | $317.24 Billion | $34.86 Billion | 0.02x | 0.21x |
Competitor Companies of AUROPHARMA by Market Capitalization
Companies near Aurobindo Pharma Limited in the global market cap rankings as of May 2, 2026.
Key companies related to Aurobindo Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Aurobindo Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Aurobindo Pharma Limited's market cap moved from $5.23 Billion to $ 8.73 Billion, with a yearly change of 5.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs8.73 Billion | +17.46% |
| 2025 | Rs7.43 Billion | -11.35% |
| 2024 | Rs8.38 Billion | +23.13% |
| 2023 | Rs6.81 Billion | +150.11% |
| 2022 | Rs2.72 Billion | -39.53% |
| 2021 | Rs4.50 Billion | -19.94% |
| 2020 | Rs5.62 Billion | +102.47% |
| 2019 | Rs2.78 Billion | -37.32% |
| 2018 | Rs4.43 Billion | +7.05% |
| 2017 | Rs4.14 Billion | +3.26% |
| 2016 | Rs4.01 Billion | -23.35% |
| 2015 | Rs5.23 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Aurobindo Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.73 Billion USD |
| MoneyControl | $8.73 Billion USD |
| MarketWatch | $8.73 Billion USD |
| marketcap.company | $8.73 Billion USD |
| Reuters | $8.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more